A recent study further documented the advantage of three years of adjuvant imatinib versus one year in high-risk GIST patients. The study, which is to be published in the Journal of Clinical Oncology, was authored by [...]
Two recent articles summarize the promise that immunotherapy provides for the future of cancer treatment. Immunotherapy refers to treatments that aid your own immune system in fighting cancer cells. The first, from U.S. News [...]
A recent study in JAMA Oncology found that patients who undergo primary GIST resection might not receive the optimal recommended duration of adjuvant therapy, which can impact their recurrence-free survival (RFS). The study was [...]
The 6th issue of the GIST Cancer Journal, official journal of the LRG and the first academic journal devoted solely to GIST is now available
Dr. Ron DeMatteo GIST specialist surgeon Dr. Ron DeMatteo, along with colleagues at Memorial Sloan-Kettering Cancer Center (MSKCC), has published a new paper in the April issue of Cancer Research with potentially [...]
In an online article, Peter Pitts, a former FDA associate commissioner, discussed the topic of off-label product claims by pharmaceutical companies. Off-label use in this case refers to using a medication for an intention [...]
The 5th issue of the GIST Cancer Journal, official journal of the LRG and the first academic journal devoted solely to GIST is now available
As personalized medicine has become an accepted paradigm, it may be time for oncologists to examine personalized dose levels.In a recent article from Cancer World, the author explores the value of therapeutic drug monitoring for [...]
A recent study published in the American Journal of Clinical Oncology found that the use of adjuvant systemic therapy with imatinib for GIST has increased significantly over time, and that patients treated with the therapy [...]
Novartis Pharmaceuticals recently received FDA approval for panobinostat, a blood cancer drug that targets multiple myeloma. This was a surprising ruling, as it was a turnaround from last year’s Oncologic Drugs Advisory Committee’s 5-2 [...]
